bioAffinity Technologies, Inc. ( (BIAF) ) just unveiled an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
bioAffinity Technologies, Inc. reports a successful year in 2024, significantly boosting sales and operations through its lung cancer detection product, CyPath Lung. The company plans to expand its market presence in 2025, leveraging its growth in the U.S. healthcare system and focusing on key regions and markets, including the VA and military sectors, to further increase the accessibility and adoption of its test.
More about bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. operates in the medical diagnostics industry, focusing on the early detection of lung cancer through its noninvasive test, CyPath Lung. The company aims to address the critical need for early cancer detection, holding patents in the U.S., the European Union, and Asia, with a significant market presence in these regions.
YTD Price Performance: -19.73%
Average Trading Volume: 140,230
Technical Sentiment Consensus Rating: Buy
See more data about BIAF stock on TipRanks’ Stock Analysis page.
Trending Articles
- Disney (NYSE:DIS) Cuts Stephanopoulos Pay Post-Trump Settlement
- Ford (NYSE:F) Quality Turns In Surprising Win
- Intel (NASDAQ:INTC) Narrows Down Altera Buyers
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
